Abstract
Elevated low‐density lipoprotein (LDL) cholesterol plays an important role in the development of atherosclerosis. In part, plasma LDL levels are dependent on cholesterol absorption in the intestine and the rate of intrinsic cholesterol synthesis. Therapy with 3‐hydroxy‐3‐methylglutaryl coenzyme A‐reductase inhibitors has often proven to be successful in reducing plasma LDL levels. However, a significant number of patients do not reach their target LDL levels despite statin therapy. As is reviewed, drugs that inhibit cholesterol absorption are a useful adjunct to lipid‐lowering therapy by statins. This review discusses the mechanisms involved in intestinal absorption of cholesterol and its transport as potential targets of newer agents that affect cholesterol absorption. The use of bile acid sequestrants and esters of plant stanols, as well as other intestinally active agents for reducing plasma LDL levels, has been limited by side effects and difficulties in patient compliance. In contrast, the new selective cholesterol transporter inhibitor ezetimibe has been demonstrated to reduce plasma LDL alone or in combination with statins without significant adverse effects. In spite of the robust lipid‐lowering data with ezetimibe, questions about clinical outcomes, safety, and efficacy in various combinations remain.
Keywords: ezetimibe, cholesterol absorption, lipoproteins, hypercholesterolemia
Full Text
The Full Text of this article is available as a PDF (31.0 KB).
References
- 1. Assmann G, Cullen P, Schulte H: The Munster Heart Study (PROCAM). Results of follow‐up at 8 years. Eur Heart J 1998; 19 (suppl A): A2–11 [PubMed] [Google Scholar]
- 2. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: Coordinating Committee of the National Cholesterol Education Program. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227–239 [DOI] [PubMed] [Google Scholar]
- 3. Pearson TA, Laurora I, Chu H, Kafonek S: The lipid treatment assessment project (L‐TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid‐lowering therapy and achieving low‐density lipoprotein cholesterol goals. Arch Intern Med 2000; 160 (4): 459–467 [DOI] [PubMed] [Google Scholar]
- 4. Kesäniemi YA, Miettinen TA: Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur J Clin Invest 1987; 17: 391–395 [DOI] [PubMed] [Google Scholar]
- 5. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP: Niemann‐Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201–1204 [DOI] [PubMed] [Google Scholar]
- 6. Turley SD, Dietschy JM: The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level. Prevent Cardiol 2003; 6 (1): 29–33 [DOI] [PubMed] [Google Scholar]
- 7. Einarsson K, Ericsson S, Ewerth S, Reihner E, Rudling M, Stahlberg D, Angelin B: Bile acid sequestrants: Mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol 1991; 40 (suppl1): S53–S58 [PubMed] [Google Scholar]
- 8. The Lipid Research Clinics Program : The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. J Am Med Assoc 1984; 251: 351–364 [DOI] [PubMed] [Google Scholar]
- 9. Nguyen TT: The cholesterol‐lowering action of plant stanol esters. J Nutr 1999; 129 (12): 2109–2112 [DOI] [PubMed] [Google Scholar]
- 10. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E: Reduction of serum cholesterol with sitostanol‐ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995; 333 (20): 1308–1312 [DOI] [PubMed] [Google Scholar]
- 11. Plat J, Kerckhoff DA, Mensink RP: Therapeutic potential of plant sterols and stanols. Curr Opin Lipidol 2000; 11 (6): 571–576 [DOI] [PubMed] [Google Scholar]
- 12. Lichtenstein AH, Deckelbaum RJ: AHA Science Advisory: Stanol/sterol ester‐containing foods and blood cholesterol levels. A statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation 2001; 103 (8): 1177–1179 [DOI] [PubMed] [Google Scholar]
- 13. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106 (15): 1943–1948 [DOI] [PubMed] [Google Scholar]
- 14. van Heek M, Farley C, Compton DS, Hoos L, Davis HR: Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001; 134 (2): 409–417 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Knopp RH, Bays HE, Manion CV: Effect of ezetimibe on serum concentrations of lipid‐soluble vitamins (abstr). Atherosclerosis 2001; 2 (suppl): 90 [Google Scholar]
- 16. Zetia (Ezetimibe) : Prescribing information. Package insert. Merck/Schering‐Plough Pharmaceuticals, 2001.
- 17. Ezzet F, Krishna G, Wexler DB, Statkevich P, Kosoglou T, Batra VK: A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 2001; 23 (6): 871–885 [DOI] [PubMed] [Google Scholar]
- 18. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP: Esetimibe Study Group: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002; 90 (10): 1092–1097 [DOI] [PubMed] [Google Scholar]
- 20. Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, Knopp RH, Lipka LJ, Lebeaut AP, Yang B, Mellars LE, Cuffie‐Jackson C, Veltri EP: Ezetimibe Study Group: Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: Pooled analysis of two phase II studies. Clin Ther 2001; 23 (8): 1209–1230 [DOI] [PubMed] [Google Scholar]
- 21. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B: Ezetimibe Study Group: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90 (10): 1084–1091 [DOI] [PubMed] [Google Scholar]
- 22. Gagne C, Gaudet D, Bruckert E, The Ezetimibe Study Group : Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105 (21): 2469–2475 [DOI] [PubMed] [Google Scholar]
- 23. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40 (12): 2125–2134 [DOI] [PubMed] [Google Scholar]
- 24. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J: Efficacy and safety of ezetimibe co‐administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004; 93: 1487–1494 [DOI] [PubMed] [Google Scholar]
- 25. Pasternak RC, Smith SC Jr, Bairey‐Merz CN, Grundy SM, Cleeman JI, Lenfant C: The American College of Cardiology/American Heart Association/National Heart, Lung and Blood Institute: ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Circulation 2002; 106 (8): 1024–1228 [DOI] [PubMed] [Google Scholar]
- 26. Ridker PM: Clinical application of C‐reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107 (3): 363–369 [DOI] [PubMed] [Google Scholar]
- 27. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C‐reactive protein on human endothelial cells. Circulation 2000; 102: 2165–2168 [DOI] [PubMed] [Google Scholar]
- 28. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S: C‐reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107 (13): 1783–1790 [DOI] [PubMed] [Google Scholar]
- 29. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr: Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators : Measurement of C‐reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344 (26): 1959–1965 [DOI] [PubMed] [Google Scholar]
- 30. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP: Ezetimibe Study Group: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double‐blind trial. Circulation 2003; 107 (19): 2409–2415 [DOI] [PubMed] [Google Scholar]
- 31. Heart Protection Study Collaborative Group : MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals: A randomised placebo‐controlled trial. Lancet 2002; 360 (9326): 7–22 [DOI] [PubMed] [Google Scholar]
- 32. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J‐C, Gotto AM, Greten H, Kastelein JJP, Shepherd J, Wenger NK, for the Treating to New Targets (TNT) Investigators : Intensive lipid‐lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435 [DOI] [PubMed] [Google Scholar]
- 33. Pedersen TR, Faergemann O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, for the Incremental Decrease in End Point Through Aggressie Lipid Lowering (IDEAL) Study Group : High‐dose atovastatin vs. usual‐dose simvastatin for secondary prevention after myocardial infarction: The IDEAL Study: A randomized controlled trial. J Am Med Assoc 2005; 294: 2437–2445 [DOI] [PubMed] [Google Scholar]